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Abstract
Background: Stress urinary incontinence (SUI) is a frequent adverse effect for men undergoing prostate surgery. A
large proportion (around 8% after radical prostatectomy and 2% after transurethral resection of prostate (TURP)) are left
with severe disabling incontinence which adversely effects their quality of life and many are reliant on containment
measures such as pads (27% and 6% respectively). Surgery is currently the only option for active management of the
problem.
The overwhelming majority of surgeries for persistent bothersome SUI involve artificial urinary sphincter (AUS) insertion.
However, this is expensive, and necessitates manipulation of a pump to enable voiding. More recently, an alternative to
AUS has been developed – a synthetic sling for men which elevates the urethra, thus treating SUI. This is thought, by
some, to be less invasive, more acceptable and less expensive than AUS but clear evidence for this is lacking.
The MASTER trial aims to determine whether the male synthetic sling is non-inferior to implantation of the AUS for
men who have SUI after prostate surgery (for cancer or benign disease), judged primarily on clinical effectiveness but
also considering relative harms and cost-effectiveness.
Methods/design: Men with urodynamic stress incontinence (USI) after prostate surgery, for whom surgery is judged
appropriate, are the target population. We aim to recruit men from secondary care urological centres in the UK NHS
who carry out surgery for post-prostatectomy incontinence. Outcomes will be assessed by participant-completed
questionnaires and 3-day urinary bladder diaries at baseline, 6, 12 and 24 months. The 24-h urinary pad test will be
used at baseline as an objective assessment of urine loss. Clinical data will be completed at the time of surgery to
provide details of the operative procedures, complications and resource use in hospital. At 12 months, men will also
have a clinical review to evaluate the results of surgery (including another 24-h pad test) and to identify problems or
need for further treatment.
Discussion: A robust examination of the comparative effectiveness of the male synthetic sling will provide high-quality
evidence to determine whether or not it should be adopted widely in the NHS.
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Background
The male synthetic sling (male sling) is an alternative
to the artificial urinary sphincter (AUS) for men with
urodynamic stress incontinence after prostate surgery,
but there is limited evidence of relative effectiveness
and cost-effectiveness to guide choice. We aim to resolve
this by directly comparing the rate of incontinence at 12
months in a non-inferiority randomised controlled trial
(RCT) powered on the basis that men would accept up to
15% lesser effectiveness in return for easier device oper-
ation and possible reduced adverse effects. We will recruit
patients who have decided, with their clinicians, that
surgery is needed. To address feasibility of recruitment,
we have devised a schedule to give early indication of our
ability to recruit to target but avoiding any disruptive
pause if we are successful.
Scale of the problem in the UK and use of NHS resources
Men undergoing radical prostatectomy for prostate cancer
frequently report the troublesome symptom of stress urinary
incontinence (SUI). Prevalence estimates vary widely
between 5% and 57% depending on definition, timing of
assessment after surgery, and population characteristics.
The rate of recovery of continence plateaus at around 12
months after surgery. This was confirmed in a recent large
HTA-funded RCT of pelvic-floor muscle training (PFMT)
in patients who suffered incontinence 6 weeks after radical
prostatectomy. Subsequently, 40% had persistent UI at 1
year, with half of these (20%) having severe UI needing
containment (incontinence pads or appliances) which then
did not improve further during the second 12 months up
to 24 months after the original surgery [1, 2].
This means that of the 6000 patients currently undergoing
radical prostatectomy in the UK each year, 1200 will be
using additional treatments for resultant stress incontinence
beyond 12 months. UI has a major impact on quality of life,
including profound loss of self-esteem together with restric-
tions on work, social interaction and personal relationships
including sexual life. The utility value associated with a
person with UI is 0.72 compared to 0.93 in a comparable
age-matched population [3]. This is particularly devastating
for men undergoing radical prostatectomy since they were
typically without any urinary problems prior to the surgery,
are fit for their age, and have a long life expectancy having
generally been cured of their prostate cancer.
Unfortunately conservative treatment with one-to-one
PFMT has been shown to be ineffective [1, 2], drug
treatment is unproven, and men mostly cope by using
containment products. Other treatments, such as inject-
ables and inflatable balloons, have been reviewed, but
there was insufficient evidence to support their use.
Surgery for persistent bothersome SUI is traditionally by
artificial urinary sphincter (AUS) as the ‘gold standard’
treatment [4]. However, this is invasive, expensive and
involves manipulation of a pump located in the scrotum
to enable voiding. Analogous to surgery for SUI in
women, synthetic slings for men have recently been
developed to elevate the urethra. This is thought by
some as less invasive, more acceptable to some men,
and less expensive, but there is no clear evidence for its
comparative effectiveness against the standard AUS.
Current NHS guidance states that the male synthetic
sling should only be used in RCTs against the AUS [5].
Approximately 350 men were implanted with an AUS in
the UK NHS during 2010 at a cost of £9000 per procedure;
£3.2 million in total. The male sling was implanted in
30 men during 2010 at a cost of £6000 per procedure;
£180,000 in total.
Evidence for surgical management for men with urinary
incontinence after prostate surgery
There are no published RCTs comparing male slings
with AUS. A Cochrane review found only one small, poor-
quality RCT of surgery which suggested that implantation
of artificial urinary sphincter (AUS) was better than an
injectable bulking agent [6]. In this RCT, the men treated
with AUS were more likely to be cured (18/20, 82%) than
those who had the injectable treatment (11/23, 46%, OR
5.67, 95% CI 1.28 to 25.10). All other evidence comes
from case series which were recently summarised by
the WHO-sponsored 4th International Consultation on
Incontinence [4]. This reported that the median (range)
cure rate after AUS was 82% (59 to 90%, 12 series) and
for male sling was 63% (13 to 86%, 20 series) [7]. A
more recent review of the academic literature looked at
six case series of men implanted with the AdVance®
brand of male sling and reported a cure rate of 60% [8].
More recently sub-group analysis from a large case
series showed that at 3 years after sling implantation,
men categorised on the basis of pad usage as having
‘mild/moderate’ incontinence, had a cure/improved rate
of 82% and those arbitrarily categorised as having severe
incontinence had a cure/improved rate of 67% [9]. These
similar cure rates, which lie within the previously reported
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range for all degrees of incontinence, support our intention
of not using the degree of incontinence as an eligibility cri-
terion. Results from a further recent case series suggest
that the outcome of implantation of AUS is not compro-
mised by previous insertion of a male sling [10]. As it is
likely that some men in our trial, randomised to sling, may
require subsequent repeat surgery, it is reassuring that
their ultimate outcome is unlikely to be worse than those
randomised to AUS.
We have analysed long-term follow-up data from men
approached for the Men After Prostate Surgery (MAPS)
trial and found that around 70% of men still reported
some urine leakage 4 to 6 years after a radical prostatectomy
(N = 579), and 39% after a transurethral resection of
prostate (TURP) (N = 1413) (unpublished data). Of this
cohort, 25% and 5% of men respectively were using
pads, and 8% and 2% had leakage several times a day of
a moderate or large amount of urine. A further 15 men
had already had an AUS operation (of whom one required
a second AUS operation), and six a male sling (of whom
one required re-intervention by implantation of an AUS).
In addition to these, a further 5% and 3% of men were
considering surgery for incontinence.
Evidence explaining why this research is needed now
The most recent Cochrane review showed that the efficacy
of conservative treatment with PFMT was still unclear
[11] and the addition of other evidence [1, 2] did not
change this conclusion. As a result, a large proportion of
men (around 8% after radical prostatectomy and 2% after
TURP) are left with disabling incontinence which ruins
their quality of life and many have no option but to
continue with containment measures (27% and 6%,
respectively) (unpublished data from 4-6 year follow up of
MAPS responders). Surgery is, therefore, currently the only
option for active management of the problem. As such, the
proposed trial will provide unique robust evidence, for pa-
tients, clinicians and healthcare policy-makers, on which to
base treatment and healthcare provision decisions.
The number of men undergoing radical prostatectomy
for localised prostate cancer is increasing (from 2500 in
2008, to 3200 in 2010 to 5600 in 2011). This trend may
continue, as localised prostate cancer case-finding using
PSA testing increases, potentially leading to more men
subsequently requiring surgery for prostate-cancer-
treatment-related urinary incontinence. As an indication,
if 50 more men required an AUS each year, this would
cost the NHS an additional £450,000. While treatment
with the male sling appears to be less expensive, the
harms, further treatment and revision surgery needs to be
taken into account to determine full comparative cost-
effectiveness.
Currently, the male sling is being offered to men seeking
treatment with the NHS on a haphazard basis according
to surgeon enthusiasm and local arrangements. Both clini-
cians and patients lack the evidence required to make an
informed choice between the two options and NHS
policy-makers lack information on cost-effectiveness to
plan service provision. The MASTER trial will fulfil the
research need identified by the recent Cochrane Review [7]
for adequately powered comparative RCTs of the surgical
options for these men. The proposed trial will determine
whether men can be confidently informed about whether
implantation of the male sling gives equivalent effectiveness
for cure of incontinence to the standard AUS. This will
allow men and their clinicians to make an informed deci-
sion regarding the individual suitability of either option,
taking into account other factors such as the relative need
for subsequent re-intervention, the need to operate a
control pump, and speedier recovery. As part of the trial
design, we will take into account the different clinical
characteristics of the men, such as type of prostate surgery,
and identify factors which may influence comparative
effectiveness, such as degree of incontinence. Affected
men, clinicians and the NHS should benefit from the
reliable evidence from the trial, to guide the choice of
treatment and healthcare provision decisions, in terms of
effectiveness, cost-effectiveness and adverse effects.
At present the design and function of the AUS appears
optimal, as, despite attempts to improve on the existing
device there are no signs of significant innovations that
would have to be considered prior or during this trial.
Sling technology, however, is less mature and we anticipate
that during the trial recruitment period, there may be a
choice of implants from different manufacturers. For that
reason we will not specify which brand of sling should be
used. However, it should be of the sub-urethral trans-
obturator type, as currently, almost all implanted slings are
of this type, and the available outcome data are chiefly for
this type of sling. We feel that this research is timely since
a robust examination of the comparative effectiveness
of this new surgical option should provide high-quality
evidence to determine whether or not it should be
adopted widely in the NHS.
For a urologist to join the MASTER study, they must be
uncertain regarding the best operative technique for
correcting the man’s incontinence, and hence be willing to
randomise the majority of patients. All the urologists must
be able to perform one or both of the two operations, and
be willing to randomise between them. Urologists must
consider themselves competent (beyond the learning
curve) and in equipoise regarding their relative merits. If
surgeons only perform one procedure, they will be teamed
with a surgeon who can perform the other.
The questions which this study will address
The aim of the trial is to determine whether the male
sling is non-inferior to implantation of the AUS for men
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who have UI after prostate surgery (for cancer or benign
disease), judged primarily on clinical effectiveness but
also considering relative harms and cost-effectiveness. In
order to determine whether the male sling or AUS is
cost-effective for the NHS in the UK, the interventions
will be compared in terms of: incontinence in men after
prostate surgery; the relative harms of the interventions;
costs to the patients, and to the NHS, including the need
for repeat surgery in both groups; and overall patient
satisfaction.
Principal objectives
1. What is the clinical effectiveness of implantation of the
male sling compared with AUS in terms of self-reported
incontinence at 12 months?
2. What is the cost-effectiveness of a policy of primary
implantation of the male sling compared with AUS,
measured by incremental cost per quality-adjusted
life-year (QALY) at 24 months?
In the long term there is a need to capture the conse-
quences of both devices. We consider the primary outcome
of the trial to be a non-inferiority comparison on rate of
incontinence at 12 months. Our reason for this
approach is that if the male sling is inferior (by at least
the agreed margin) in the short term, then male slings
will highly likely not be introduced throughout the
NHS, irrespective of longer-term costs and consequences.
However, if the difference in effectiveness is within the
non-inferiority margin, the cost-effectiveness analysis, using
outcomes over 24 months, will be required to decide on
the relative worth of the interventions to the NHS.
Secondary objectives
3. What are the harms of each type of surgery?
4. What are the costs of the benefits and harms of each
treatment policy?
5. What subsequent NHS services (including repeat
surgery) are needed for men with persistent or
recurrent problems?
6. What are the differential effects of the operations on
other outcomes such as quality of life and general
health?
7. How satisfied are the participants with each
procedure?
In addition, a qualitative component has been embedded
within the trial to establish patient-perceived importance
of different outcomes, explore patients’ and surgeons’
perspectives on experiences of procedures and acceptable
inferiority margins, and determine reasons for failure
resulting in crossover to alternative surgery.
Methods/design
Study design
This trial comprises a multicentre, randomised controlled,
non-inferiority trial of surgery for men with UI after prostate
surgery. The trial structure is presented in Fig. 1 (flow
diagram). The rationale for our proposed trial design
reflects the uncertainties in the evidence base in this
clinical area.
Closure of the non-randomised cohort
The initial MASTER protocol included a non-randomised
cohort (NRC) of men who did not agree to randomisation
but did agree to having baseline measurements and
follow-up by questionnaire. The men already recruited to
the NRC have made significant contributions and will
continue to be followed up. In addition, the men in the
NRC have provided valuable data in the initial phase of
qualitative research that will help to answer the questions
listed in the qualitative research section.
Qualitative research
A significant qualitative component is proposed for this
study to underpin its development and to inform how
best to interpret the results of the trial. The main aims
of the qualitative components are:
Fig. 1 Flow diagram of study design and schedule
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1. To establish the importance of the main outcomes to
patients undergoing treatment for post prostate
surgery incontinence (during trial set-up at pilot sites)
2. Explore how to most appropriately evaluate
non-inferiority of the procedures from the patients’
perspective using patients who were both prepared and
not prepared to be randomised (before randomisation;
and after refusal of randomisation. Those who refused
randomisation had consented to follow-up in the
non-randomised cohort while that part of MASTER
was open, up to and including 27 October 2015)
3. Explore the patient experience of the two procedures
4. Explore patients’ reasons for requiring reoperation;
for example, those choosing to have an AUS after a
failed sling procedure
5. Explore the experience of surgeons with both
procedures
Further details of the qualitative study are given in
Additional file 1 (Study protocol; Appendix 2: Qualitative
Study).
Methodological research
The responses from participants and the objective findings
from pad tests and urinary diaries will provide a rich data
source for exploration of the correlation between patient-
reported and objective outcomes, and between urinary
and sexual symptoms and their effect on quality of life.
This methodological research is intended to advance the
controversial field of outcome measurement in lower
urinary tract dysfunction, and will build upon our existing
work in this area.
Target population
Men with SUI after prostate surgery (radical prostatectomy
or TURP), for whom surgery is judged appropriate, are the
target population. For the purposes of the trial we will de-
fine men with mild incontinence as those not requiring
surgery. There is no clear threshold for defining moderate
or severe incontinence and no clear evidence of differential
benefit for either intervention according to degree of
incontinence. We will, therefore, include all men whose
incontinence is considered, from both the patient and
surgeon perspectives, to require surgery.
Setting
Participants will be recruited from NHS secondary care
urological centres throughout the UK. Discussions at a
number of meetings facilitated by the relevant professional
organisation, British Association of Urological Surgeons
(BAUS), has gained consensus from urologists that they
would be willing to randomise participants to either
option. Participants will be referred by their oncological
urologist, specialist cancer nurse or local urologist or
continence advisor. The BAUS Section of Oncology and
the Section of Female Neurological and Urodynamic
Urology have been kept fully involved during the planning
of this trial and have given the study their full support.
However, the applicants have collaborations with colleagues
throughout Europe, particularly in Belgium and The
Netherlands and the protocol would be made available
for their participation, if agreed, and separately funded.
Planned interventions
Two surgical operations for male UI, the experimental
technique of synthetic male sling, and the standard tech-
nique of AUS implantation will be evaluated. Divergence
from pre-specified choices will be documented with
reasons. All other operative variables will be described
using standardised data collection forms. The surgical
options have been agreed and standardised by consensus
within the research team and with the recruiting
urologists.
Male synthetic sling (male sling)
The male sling costs approximately £6000 per procedure
(NHS tariff + device cost of £2000) with a typical 1-day
hospital stay. It is placed under the urethra to elevate it
and is held in place by passing it through the obturator
foramen of the pelvic bone bilaterally. It has a passive
mode of action. The aim is to stop the loss of urine on
exertion and the operation is effective immediately.
Artificial urinary sphincter (AUS)
The artificial urinary sphincter (AUS) costs approximately
£9000 per procedure (NHS tariff + device cost of £4500)
with a typical 2-day hospital stay. It consists of an inflatable
cuff placed around the urethra, a pressure regulating
balloon to keep the cuff inflated, and a pump, placed in
the scrotum, that the patient squeezes when they need
to void. The aim is to close the urethra so that the patient
is dry except when they wish to void. Once implanted the
device is deactivated in the open position for a period of
approximately 4 to 6 weeks to allow post-operative swelling
to subside. The patient then returns to hospital for the
device to be activated and to ensure that they are able to
use the device correctly.
Planned inclusion/exclusion criteria
Inclusion criteria
1. Adult men who have decided in discussion with
their urologist to have surgery for urodynamic stress
incontinence (USI) resulting from prostate surgery
2. Men who are willing to be randomised between
male sling and AUS
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Exclusion criteria
1. Men who have had previous male sling or AUS
surgery
2. Men with unresolved bladder neck contracture or
urethral stricture after prostate surgery
3. Men who do not consent to be randomised
4. Men with insufficient manual dexterity to operate
AUS device
5. Men who are unable to give informed consent or
complete trial documentation
Allocation to trial groups
All eligible men referred for consideration of incontinence
surgery will be identified by the consultant, dedicated
research nurse, or designated team member at pre-
assessment clinics, urodynamic clinics and outpatient
urology clinics in each centre. The consultant/research
nurse will introduce the trial to the patients and, if
interest is expressed, provide details of the trial by
means of the Patient Information Leaflet (PIL). Each
patient will have the opportunity to discuss the trial with
the local clinical team. Patients may make a decision to par-
ticipate during this consultation, at a separate appointment,
at a pre-admission clinic or while at home or on admission
for their operation. Men who agree to be contacted at
home may receive a telephone call from the local research
nurse to discuss any queries. Patients who decide to partici-
pate following telephone counselling can either send their
completed documents (consent and baseline questionnaire)
through the post to the local team at their treating hospital
or bring it with them if they are returning to hospital for
another consultation or treatment. The 24-h test pads will
also need to be taken into hospital for weighing at clinic
visits, on the day of operation or information about the pad
weight collected by telephone prior to this date.
Each man will be asked for his signed informed consent
to be randomised and followed up after surgery by postal
questionnaires and clinical review. The PIL and the consent
form will both refer to the possibility of long-term follow-
up and being contacted about other research if the man is
willing, e.g. data collection from hospital and NHS records,
including Office of National Statistics (ONS) and NHS
central registers.
All participants who enter the trial will be logged with
the central Study Office and given a unique Study Number.
Randomisation will utilise the existing proven remote
automated computer randomisation application at the
study administrative centre in the Centre for Healthcare
Randomised Trials (CHaRT, a fully registered UK CRN
clinical trials unit) in the Health Services Research Unit,
University of Aberdeen. This randomisation application
will be available both as a telephone-based Interactive
Voice Response (IVR) system and as an Internet-based
service.
Randomisation will be computer-allocated and
minimised on:
 Type of prostate surgery (radical prostatectomy or
TURP)
 Whether or not they have had radiotherapy in
addition to surgery
 Centre
All participants who consent to enter the trial will
complete baseline questionnaires, including measurement
of urinary and sexual symptoms, a urinary bladder diary,
and have an objective 24-h pad test carried out prior to
randomisation. Participants who consent to randomisation
will then be randomised to receive a male sling or AUS.
Methods to protect against sources of bias
Randomisation (avoiding selection bias)
Participants will be logged and registered on the trial
database prior to trial entry. Randomisation will be by
secure remote third-party either via computer allocation
using a web application or telephone. Randomisation
will be carried out as close to the time of surgery as is
practical, taking into account the standard procedures in
each centre for ordering implants and arranging theatre
schedules.
Ensuring standardisation of intervention and outcome
measurement (performance bias)
Investigators The basic acceptance criteria for partici-
pating urologists is that they must be uncertain regarding
the best operative technique for the majority of patients,
and they must be competent to perform the operations to
be compared (i.e. beyond the learning curve), as judged by
themselves and/or trial-appointed trainers. The investiga-
tors are specialist urologists who will be responsible for
recruiting and randomising men. All will be experienced
in performing both operations, or if a surgeon performs
only male sling or AUS, then they will be ‘paired’ with a
local urologist who performs the other procedure, thereby
guaranteeing that all participants will be operated on by
the surgeon experienced in the operative technique to
which he is randomised.
Standardisation of surgical techniques The surgical
procedures and other operative variables have been stan-
dardised as much as possible by using agreed protocols
developed by the urological grant holders (Professors
Abrams, Drake, Mundy and Pickard). Any deviations
from agreed protocols will be recorded. All investigators
are experienced urological surgeons. Investigators, who
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are experienced in male sling surgery, will deliver any
additional training if required. The clinical grant applicants
will ensure standardisation of existing techniques and out-
come measures, including the use of new devices.
The research nurses and/or the surgeons will complete
a theatre Case Report Form (CRF) at the time of surgery,
to ensure a complete record of all surgical techniques
and materials used, and any intra-operative difficulties
or complications. The research nurses in each centre will
ensure completeness and accuracy of data entry using
remote data capture via a trial web-based portal at the
Study Office in Aberdeen, authored and managed by
the Centre for Healthcare Randomised Trials (CHaRT),
the UK CRN-registered trials unit in Aberdeen.
As this is a pragmatic trial, post-operative care will
be according to local centre practice, but clinical and
resource-use data will be recorded.
Loss to follow-up (attrition bias)
Loss to follow-up in our previous trial of conservative
treatment for men with UI after prostate surgery [1, 2]
was 5 to 10% at 1 year. However, a less optimistic estimate
of 15% loss to follow-up has been used in the sample size
calculations. We will take very active measures to minimise
such loss, such as phoning the participants, using retention
incentives and checks with their general practitioners
(GPs). In addition, we will obtain consent from the
participants to enable us to access centrally held NHS
data; for example, via the NHS Strategic Tracing Service
in England and Wales, and using Community Health
Index (CHI) numbers from the Information Services
Division in Scotland.
Other sources of bias (detection bias)
After randomisation, participants will not be told of their
allocation before surgery unless they specifically request
this information. Blinding in theatre is not possible given
that this is a surgical procedure trial with different
implantation devices. After surgery, group allocation
cannot be concealed from the participant or the ward
staff due to the nature of the device. Outcome assessment
is largely by participant self-completed questionnaire, so
avoiding interviewer bias.
Research staff will be blinded to allocation while
conducting data collection for outcomes (e.g. pad test
weighing), performing data entry and analysis, and by
using Study Numbers only to identify participants, ques-
tionnaires, diaries and pads. Participants will be asked not
to reveal information about their surgical treatment. Staff
will be asked to record whether or not they knew which
operation was performed before undertaking outcome as-
sessments. All participants will be actively followed up,
with analysis based on the intention-to-treat principle.
All analyses will be clearly predefined to avoid bias.
Sample size
There is a lack of robust evidence from comparative
studies on which to base the trial sample size calculation.
For the primary outcome (incontinence), limited evidence
from case series suggests that 20% of men would still be
incontinent 12 months after AUS. For male slings, after
primary implantation the percentage of men who are
incontinent is thought to be 35%.
For our chosen non-inferiority comparison at 12 months,
a trial with 310 participants will allow us to be 90% sure
that the lower limit of a two-sided 95% confidence interval
will exclude the possibility that the AUS is more effective
by a margin of 15% or more. Allowing for 15% loss to
follow-up after enrolment we plan to recruit 180 partic-
ipants per group into the trial. This sample size will
allow the detection of a difference equivalent to 0.25 of
a standard deviation (SD) at 80% power between the
groups for the key secondary outcome, International
Consultation of Incontinence Questionnaire (ICIQ) at
24 months.
Subsequent arrangements
Informing key people
Following formal trial entry:
The Study Office will:
1. Inform the participant’s GP (by letter) enclosing
information about MASTER and the Study Office
contact details
The local research nurse/recruitment officer and/or
urologist will:
1. File the hospital copy of the consent form in the
hospital notes along with information about MASTER
2. Inform the ward and theatre staff as appropriate of
the participant’s entry to the trial and details of the
intervention allocation (theatre only)
3. Use the MASTER Internet database to enter data
regarding the participant, including data required to
complete randomisation; and intra-operative and
post-operative information abstracted from local
medical records
4. Maintain and archive study documentation at the
site. A copy of the signed consent form is returned
to the Study Office in Aberdeen after database entry
Monitoring the participants
Participants will be contacted by telephone, post or
email as appropriate. In case of non-return of question-
naires, or non-attendance at outpatient appointments,
attempts will be made by staff at the Study Office to
trace the participant directly using these means or
indirectly by contacting the GP.
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Notification by GPs
GPs are asked to contact the Study Office if the participant
moves, becomes too ill to continue or dies, or any other
notifiable or adverse event occurs. Alternatively, staff at the
Study Office may contact the GP.
Offices for National Statistics (HES (Hospital Episode
Statistics) data in England, ISD (Information Statistics
Division) data in Scotland)
Consent will be sought from all participants to trace
their medical records and addresses from local records
and centrally held computerised databases. This should
facilitate long-term follow-up.
Ethical arrangements
We believe that the proposed research does not pose
any specific risks to individual participants nor does it
raise any extraordinary ethical issues.
Data collection and processing
Follow-up will continue for 24 months from the date of
randomisation including those who agreed to enter the
non-randomised cohort whist that part of MASTER was
open (up to and including 27 October 2015). It is not
part of this protocol or the current study to follow up
the men beyond this time. However, consent will be
sought to make this possible in the future, and long-term
follow-up is planned.
Proposed outcome measures
The outcomes are similar to those piloted and used
successfully in MAPS, with the addition of relevant
surgical outcome measures. The primary outcome uses
the ICIQ-UI Short Form (SF).
Primary outcome measures
The primary clinical outcome is participants’ report of
UI at 12 months measured by a response indicating any
loss of urine to either of the two questions: ‘How often
do you leak urine?’ and ‘How much urine do you leak?’
in the validated ICIQ-SF [12].
The primary economic outcome measure of cost-
effectiveness is incremental cost per QALY at 24 months
based on responses to the EuroQol Group’s five-dimension
health status questionnaire (EQ-5D™) [13].
Secondary outcome measures
General
 Immediate and late post-operative morbidity; blood
loss
 Complications related to devices. e.g. urethral
erosion or infection
 Other adverse effects or complications
 Operating time
 Length of hospital stay
 Number of readmissions to hospital
 Time until resumption of usual activities
 Need for further surgery for urinary incontinence
 Time to further surgery
 Satisfaction with treatment (ICIQ-satisfaction)
Urinary outcomes
 Urinary incontinence (ICIQ-UI SF Score and types
of incontinence)
 Use of pads
 24-h pad test (weight of urine lost)
 Lower urinary tract symptoms (frequency, nocturia,
urgency, and voiding symptoms such as slow stream
and hesitancy (ICIQ-Male Lower Urinary Tract
Symptoms (MLUTS)).
Sexual function outcomes
 Sexual function (ICIQ-MLUTSsex)
Quality-of-life outcome measures
 Condition-specific quality-of-life measures (incontinence
from ICIQ-UI SF, and sexual from ICIQ-MLUTSsex)
 General health measures (SF12 and EQ-5D)™
Economic outcome measures
 Need for alternative management for incontinence
or voiding dysfunction (e.g. PFMT; further surgery;
use of pads, drugs, or sheath, indwelling or
intermittent catheters)
 Cost and use of NHS services
 Cost to the participants and their families/carers
 QALYs estimated from the responses to the EQ-5D™
 The incremental costs, QALYs and incremental cost
per QALY derived by the economic model over a
longer-term time horizon
In addition, all participants who have surgery (including
non-randomised men who entered the NRC while it was
open) will be asked to consent to long-term follow-up,
including the use of computerised NHS records and other
routine data sources.
Measurement of outcomes (Fig. 2)
Outcomes will be assessed by participant-completed
questionnaires and 3-day urinary bladder diaries at base-
line, 6, 12 and 24 months. The 24-h urinary pad test will
be used at baseline as an objective assessment of urine
loss, measured by pad weighing in grams per 24 h. The
research nurse and/or urologist will complete a CRF at
the time of surgery providing details of the operative
procedures, complications and resource use in hospital.
At 12 months the randomised men will also have a
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review appointment with their urologist and/or research
nurse to evaluate the results of surgery (including
another 24-h pad test), and to identify problems or the
need for other treatment. This may occur via the telephone
if participants have already been discharged by the local
centre before this date or pads weighed at a non-research
centre closer to their home (provided the equipment used
to do this is sufficiently accurate).
Economic outcomes will be assessed using standard
economic methods plus trial-specific data collection
described earlier. We are using standardised outcome
instruments developed by the International Consultation
on Incontinence (ICI) for urinary and sexual symptoms
[12]. The components and timing of follow-up measures
are shown in Fig. 2 (Standard Protocol Items: Recommen-
dations for Interventional Trials (SPIRIT) Figure [14]).
Questionnaires and Case Report Forms (CRFs)
Questionnaires for participants
Participants will be asked to complete a baseline ques-
tionnaire and diary before surgery. Content will include:
1. Healthcare utilisation questions (including GP
consultations and hospital visits/admissions, use of
other services)
2. Personal costs (pad use, catheter use, over-the-counter
medication, other healthcare services)
3. EQ-5D™
4. Urinary symptoms (ICIQ-MLUTS, urinary leakage
ICIQ-UISF, and effect on quality of life, ICIQ-qol,
http://www.iciq.net/structure.html)
5. Sexual symptoms (ICIQ-MLUTSsex); http://
www.iciq.net/ICIQ.MLUTS.html
The follow-up questionnaires and diaries at 6, 12 and
24 months will repeat the baseline questions and, in
addition, will enquire about:
1. Complications and adverse effects
2. Need for further treatment for incontinence or
complications, including further surgery
The follow-up questionnaire at 12 and 24 months will
repeat the questions and in addition will enquire about:
1. Satisfaction with surgery results and willingness to
recommend to a friend
Urinary diaries
Participants will be asked to complete urinary diaries
at each questionnaire time point, including frequency
of micturition, leakage and nocturia, use of pads and
wetting of clothes.
Case Report Forms (CRFs)
Baseline CRF
At baseline, the urologist and/or research nurse will
complete a CRF with the following content:
Pre-operative
1. Contact details, GP address, telephone numbers
2. Urological and surgical history
3. Urodynamics
4. Pad tests
Intra-operative
1. Intra-operative data including date of admission and
operation
2. Operative procedures and theatre time
3. Catheter use
4. Complications
Post-operative
1. Pain relief, infection, haematoma, other
complications
2. Date of discharge
12-month clinical review assessment form
At 12 months after surgery, all men will be reviewed by
the urologist and/or the research nurse:
1. Clinical findings (pad tests)
2. Complications and adverse events
Fig. 2 Standard Protocol Items: Recommendations for Interventional
Trials (SPIRIT) Figure: trial timeline for recruitment, intervention,
assessment and follow-up
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Serious adverse event (SAE) Case Report Form
Serious adverse events will be coded and recorded using
a standard SAE CRF at the behest of a local urologist.
The SAE form will be used to record details of any ser-
ious adverse events related to the incontinence surgery/
procedure undertaken as part of MASTER.
HES and ISD data
After the last man has been recruited, we will run periodic
checks for operations, diagnoses and hospital admissions
with centrally collected data, to supplement and validate
data collected from the participants, and to set up mecha-
nisms for long-term follow-up.
Data processing
Research nurses will enter locally collected data in the
centres. Staff in the Study Office will work closely with
local research nurses to ensure that the data are as
complete and accurate as possible. Follow-up question-
naires to men will be sent from, and returned to, the Study
Office in Aberdeen. Extensive range and consistency
checks will further enhance the quality of the data.
Withdrawal procedures
Participants may withdraw from any aspect of the trial.
Analysis plans
Statistical analysis
All analyses will be based on the intention-to-treat
principle, analysing participants in the groups to which
they were randomised. All missing data will be imputed
at baseline using appropriate imputation methods. Missing
items on the health-related outcome measures will be
treated as per the instructions for that particular measure
but without imputation for other missing follow-up data.
All outcomes will be described with the appropriate
descriptive statistics where relevant: mean and standard
deviation for continuous and count outcomes, or medians
and inter-quartile range if required for skewed data;
numbers and percentages for dichotomous and categor-
ical outcomes (for example, subjective recurrence of
incontinence).
Analysis of the primary outcome (number of participants
with UI) will estimate the mean differences at 12 months
after surgery (and 95% confidence intervals) between the
two intervention groups using a general linear model that
adjusts for the minimisation covariates and other important
prognostic covariates, including the baseline symptom
score, at 12 months after surgery. A two-sided statistical
significance (2P < 0.05) will be sought. A similar analysis
will be used to analyse the data at 6 and 24 months.
All secondary outcomes will be analysed in a similar
manner but using the appropriate generalised linear model
(for example, logistic regression for dichotomous data such
as subjective failure, Poisson or negative binomial regres-
sion for count data such as number of nights in hospital)
or time to event methods (e.g. Cox regression on time to
further surgery) where required. We will explore analysing
outcomes at all time points simultaneously using, for
example, Generalised Estimating Equations or Generalised
Linear Latent and Mixed Models, and relevant link
functions to explore changes in outcome over time.
Further details about the statistical analysis will be outlined
in the Statistical Analysis Plan.
Planned subgroup analyses
Subgroup analysis according to type of prostate surgery
will be considered within the following groups:
 Radical prostatectomy or TURP
 Amount of urine leaked per 24 h at baseline, above,
and below or equal to 250 g per 24 h
Heterogeneity of treatment effects amongst subgroups
will be tested for using the appropriate subgroup by treat-
ment group interactions [15]. Stricter levels of statistical
significance (2P < 0.01) will be sought, reflecting the
exploratory nature of these analyses.
All study analyses will be according to a Statistical
Analysis Plan that will be agreed in advance by the Trial
Steering Committee (TSC) and the Data Monitoring
Committee (DMC).
Proposed frequency of analyses
A single main analysis will be performed at the end of the
trial when all 24-month follow-up has been completed.
An independent DMC will review confidential interim
analyses of accumulating data at its discretion but at least
annually. A major consideration for the DMC will be
to monitor the 12-month primary outcome (i.e. the
non-inferiority margin).
Economic evaluation
The trial will include a formal economic evaluation
assessing the costs and cost-effectiveness of the inter-
ventions compared from the perspectives of the NHS
and the participants and their families. Resource-use
data collected will include the cost of the intervention
and the use of primary and secondary NHS services by
the participants, including further referral for subse-
quent additional specialist management. Health service
costs refer to those incurred directly by the NHS due to the
surgery and subsequent appointments and procedures.
Personal costs to the participants (such as costs of travelling
to appointments and work/social restrictions) will also be
investigated.
Resource use will be recorded prospectively for every
participant within the study. For the surgical interventions,
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operative details will be recorded at the time of surgery
(e.g. time the surgery takes, the time spent in recovery,
grade of surgeon and assistant, grade of anaesthetist). A
parallel exercise will establish resources used immediately
before, during and after (i.e. in recovery) the operation, e.g.
other staff, consumables (surgical requisites) and capital
(costs associated with using the theatre facilities, costs of
using reusable equipment). Costs to the participants will
be collected using a questionnaire based on one developed
by the UK working party on patient costs. The use of sec-
ondary care services (e.g. length of hospital stay, outpatient
appointments, and readmission) will be abstracted from
patient notes or questionnaires. The use of primary care
services, including medications prescribed will be collected
using a patient questionnaire. Unit costs/prices will be
obtained using published estimates for healthcare services
and/or interventions.
A generic instrument (the EQ-5D™) will be used to
measure health state. Trial participants will be asked to
complete the EQ-5D™ at baseline and at 6, 12 and 24
months after their operation. This instrument will provide
the quality of life weights to compute the QALYs.
Incremental cost-effectiveness ratios will be computed
comparing the cost of the interventions. The difference
in effectiveness will be expressed in terms of the number
of participants who are still incontinent at 24 months.
These data will be based on responses to either of two
questions relating to the loss of urine, retrieved from the
participant questionnaires. Incremental cost-utility ratios
will be computed comparing the interventions. The
difference in utility will be expressed in terms of QALYs
at 24 months. Where appropriate, the analysis of incre-
mental costs, effectiveness and cost-effectiveness will be
based on similar statistical models as those outlined in
the Statistical Analysis Plan above. This ‘within’ trial
analysis will include both deterministic and stochastic
sensitivity analyses to explore statistical and other forms
(e.g. around unit costs or the source of utility estimates)
of uncertainty.
An economic model which considers a longer time
horizon will also be developed to provide additional infor-
mation for policy-makers. In the model, the findings of the
trial will be extrapolated to the participant’s life time. The
model will describe care pathways that men may follow
and will include the initial surgery and any subsequent
treatments. The structure of the model will be developed
in collaboration with the expert panel of service users,
patients, clinicians and trial collaborators. Parameter
estimates for relative effectiveness up to two years,
costs and utilities will be derived from the trial data.
Data from the trial will be supplemented with data
from other sources (e.g. Cochrane review, other future
RCTs). These data will be assembled systematically and
will follow guidelines for good practice [16].
Outcomes in the model will be expressed in terms of
an incremental cost per QALY. Parameter uncertainty
will be integrated by the incorporation of probability
distributions into the model and involve Monte Carlo
simulation. Other forms of uncertainty, such as that
associated with choices made about the structure of the
model, discount rate, etc. will be addressed through
sensitivity analysis. The base case and sensitivity analyses
will be presented as cost-effectiveness acceptability
curves. The model will also be used to identify priorities
for further research by investigating the expected value
of information.
Recruitment rates and milestones
Figure 3 shows the projected recruitment of centres and
participants, and the projected number of men to be
approached. Five centres will be established relatively
early in the project as an internal pilot followed by roll
out to the others over the subsequent months.
An internal pilot is included, primarily designed to
verify that recruitment is possible. We will make a deci-
sion about feasibility at around month 15 when 82
centre months have been accrued and approximately 43
participants randomised. We anticipate that this should
include ‘steady state’ data from the five selected pilot
centres and initial data from up to 10 other centres
more recently set up. This rule will try to statistically
assess the accumulating recruitment to see if it is
consistent with the required rate to recruit on time and
budget to the full trial. It would take the form of ‘If
recruitment is at least 37 of the anticipated 43, continue
unchanged to full study; if between 26 and 36, then
consider modifying the design; if 25 or less, consider
that the trial is not feasible’. If the trial progressed as
planned we would anticipate having 117 randomised
participants by month 24, 281 patients by month 36
and the remaining 79 patients by month 42, making a
total of 360 participants.
Extension to recruitment
Due to the slower than anticipated recruitment, a 9-month
extension has been approved. Based on a conservative
estimate of the recruitment trend, nine randomised partici-
pants per month, for an additional 9 months will resulted
in achieving target recruitment (Fig. 3).
The funding for the trial started on 1 September 2013
and the duration is 82 months. The Gantt Chart (Fig. 4)
illustrates the main milestones: pre-funding: multicentre
research ethics and central Research and Development
(R&D) approvals; months 1–6: set-up office, assemble
team, and establish the first five centres; months 7–16:
aim to establish the trial in all centres; months 7–51:
identify and recruit 360 participants; months 13–75:
follow-up at 6, 12 and 24 months after surgery; months
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76–87: final reminders; months 76–82: complete data
collection, analysis and dissemination.
The trial will continue to 31 May 2020 with the possi-
bility of longer-term follow-up through a separate fund-
ing application.
Organisation
A detailed plan and timetable of study organisation is
given in the Gantt chart (Fig. 4).
The Gantt chart indicates when it is anticipated that
the major study events will occur, including recruitment,
trial progress and meetings. There will be approximately
3-monthly project management group meetings, six
meetings of the Steering Committee and four of the
Data Monitoring Committee. Two meetings are planned
for collaborators (including urologists, local research
nurses and consumer participants); the first, timed to
occur when all the sites have been identified, and the
second when results are available. There will also be a
training meeting for the recruitment nurses.
These time-related milestones will be used to enable
close monitoring of progress.
Local organisation in centres
Lead urologist (local principal investigator)
Each collaborating centre will identify a lead urologist
who will be the point of contact for that centre.
The responsibilities of this person will be to:
 Establish the study locally (for example, by getting
agreement from clinical colleagues; facilitate local
regulatory approvals; identify, appoint and train a
local research nurse; and inform all relevant local staff
about the study (e.g. other consultant urologists,
junior medical staff, secretaries, ward staff)
 Take responsibility for clinical aspects of the study
locally (for example, if any particular concerns occur)
 Identify patients who are eligible to participate in the
trial, explain the different surgery options to them, and
Fig. 3 Site accrual and recruitment projections
Fig. 4 Gantt chart
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ensure that study documentation has been provided
and that informed consent has been obtained
 Notify the Study Office of any unexpected, serious
clinical events which might be related to trial
participation and assess the implications of events
leading to these for the safety of other trial
participants
 Provide support, training and supervision for the
local research nurse(s)
 Represent the centre at the collaborators’ meetings
Local research nurse
Each collaborating centre will appoint a local research
nurse to organise the day-to-day recruitment of partici-
pants to the trial.
The responsibilities of this person will be to:
 Keep regular contact with the local lead urologist,
with notification of any problem or unexpected
development
 Maintain regular contact with the MASTER Study
Office
 Keep local staff informed of progress in the trial
 Contact potential participants by: providing the PIL
to patients being admitted electively for UI surgery;
identifying any eligible patients at pre-assessment
clinics or on the ward while they are in hospital for
their surgery; explain the study and the potential for
participation in a trial if they are eligible; explaining
what is intended by research access to their NHS
data; and describing the possibility of long-term
follow-up and participation in other research
 Obtain the patient’s written consent
 Keep a log of whether eligible men are recruited or
not (with reasons for non-participation)
 Collect baseline data describing the participants, log
this information in the web-based MASTER data-
base and send paper copies to the Study Office along
with the original signed consent forms in a timely
manner
 Use this information to randomise the participants
using the web-based MASTER database or
telephone
 Ensure operative and post-operative data (including
12-month clinic CRF hospital readmission form,,
withdrawal form and SAE form) are collected and
recorded in the web-based MASTER database, and send
paper copies to the Study Office in a timely manner
 File relevant study documentation (e.g. consent
forms) in the participant’s medical records
 Organise and supervise alternative recruiters in case
of holiday or absence
 Represent the centre at the collaborators’ meetings
Study co-ordination in Aberdeen
The Study Office Team
The Study Office is in CHaRT, Health Services Research
Unit in Aberdeen and provides day to day support for
the clinical centres. It is responsible for all data collection
(such as mailing questionnaires), follow-up, data processing
and analysis. It is also responsible for providing and main-
taining the randomisation service, and communicating with
the sites about MASTER-specific issues. We will pro-
duce a yearly MASTER Newsletter for participants and,
in addition, regular meetings with research nurses and
local collaborators to inform everyone of progress and
maintain enthusiasm.
The MASTER Study Office Team (Aberdeen-based
grant holders and study office members, plus the chief in-
vestigator (CI)) will meet formally approximately monthly
during the course of the study to ensure smooth running
and trouble-shooting.
The Project Management Group (PMG)
The study is supervised by its Project Management
Group. This consists of the grant holders and represen-
tatives from the Study Office. Observers may be invited
to attend at the discretion of the Project Management
Group. They plan to meet or hold a teleconference every
3 months on average.
The Trial Steering Committee (TSC)
The study is overseen by an independent Trial Steering
Committee (TSC). The membership comprises the four
independent members (including the Chairman), and
the CI (or a deputy). The other grant holders, a represen-
tative from the sponsoring institution and the funders (the
HTA) may also attend, as may other members of the
MASTER Study Office or members of other professional
bodies at the invitation of the Chair.
Research governance, data protection and sponsorship
Research governance
The trial will be run under the auspices of CHaRT based
at the Health Services Research Unit, University of
Aberdeen. This will ensure compliance with Research
Governance, and provide centralised trial administration,
database support and economic and statistical analyses.
CHaRT is a registered Clinical Trials Unit with particular
expertise in running multicentre RCTs of complex and
surgical interventions.
The CI will ensure, through the TSC, that adequate
systems are in place for monitoring the quality of the
study (compliance with good clinical practise (GCP)) and
appropriate expedited and routine reports of adverse
effects, to a level appropriate to the risk assessment of the
study.
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Data protection
The trial will comply with the Data Protection Act 1998
and regular checks and monitoring are in place to ensure
compliance. Data are stored securely in accordance with
the Act and archived to a secure data-storage facility. The
consent form will state that other researchers may wish to
access (anonymised) data in the future. The senior IT
manager (in collaboration with the CI) will manage access
rights to the data set. Prospective new users must demon-
strate compliance with legal, data protection and ethical
guidelines before any data are released. It is anticipated
that anonymised trial data will be shared with other
researchers to enable international prospective meta-
analyses.
Sponsorship
The study is sponsored by the North Bristol NHS Trust.
Retention of data
It is intended to follow-up the whole cohort of participants
for at least 10 years, and data will be retained as long as
necessary for this purpose. Permissions will be sought from
the relevant research governance bodies and the Ethics
Committee.
Data and safety monitoring
Data Monitoring Committee
There is a separate and independent Data Monitoring
Committee (DMC). It is anticipated the members will
meet once to agree terms of reference and on at least
three further occasions to monitor accumulating data
and oversee safety issues. This committee is independent
of the study organisers and the TSC. During the period
of recruitment to the study, interim analyses will be
supplied, in strict confidence, to the DMC, together
with any other analyses that the committee may request.
This may include analyses of data from other comparable
trials. In the light of these interim analyses, the DMC will
advise the Steering Committee if, in its view:
1. One of the methods of surgery has been proved,
beyond reasonable doubt,1 to be different from the
control (standard management) for all or some types
of participants (in respect of either effectiveness or
unacceptable safety concerns), and
2. The evidence on the economic outcomes is
sufficient to guide a decision from healthcare
providers regarding recommendation of which
operation to choose
The TSC can then decide whether or not to modify
intake to the trial. Unless this happens, however, the
TSC, PMG, clinical collaborators and Study Office staff
(except those who supply the confidential analyses) will
remain ignorant of the interim results.
The frequency of interim analyses will depend on the
judgement of the Chairman of the DMC. However, we
anticipate that there might be two interim analyses and
one final analysis.
The Chairman and the other independent members
are appointed after confirmation by the HTA.
Safety concerns
The MASTER trial involves surgical operations for UI
which are established in clinical practice. Adverse effects
may occur after any type of surgery. The relevant guidelines
for reporting serious adverse events will be followed.
Collaborators and participants may contact the Chairman
of the TSC through the Study Office about any concerns
they may have about the study. If concerns arise about pro-
cedures, participants or clinical or research staff (including
risks to staff) these will be relayed to the Chairman of the
DMC.
Safety definitions
An adverse event (AE) is defined as any untoward medical
occurrence in a participant, not necessarily having a causal
relationship.
Adverse events are not:
 Continuous and persistent disease or symptom,
present before the trial, which fails to progress
 Signs or symptoms of the disease being studied (in
this case incontinence), or
 Treatment failure
An adverse event is defined as ‘serious’ (SAE) if it:
 Results in death
 Is life threatening
 Requires or prolongs inpatient hospitalisation
 Results in persistent/significant disability/incapacity
 Is otherwise considered medically significant by the
investigator
Within MASTER, an adverse event is defined as
‘related’ if it occurs as a result of a procedure required
by the protocol, whether or not this procedure is the
specific intervention under investigation and whether
or not it would have been administered outside the
study as normal care.
Expected adverse events In this study the following
adverse events are potentially expected:
Possible (expected) adverse events during or associated
with surgery include:
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 Excess blood loss (> 500 ml) or transfusion
 Injury to organs (e.g. bladder, bowel, urethra), blood
vessels or nerves
 Anaesthetic complications
 Death
Possible (expected) adverse events following surgery
include:
 Excess blood loss (> 500 ml)
 Blood transfusion
 Haematoma formation
 Prolongation of post-operative catheterisation
 Recatheterisation
 Urinary retention/voiding difficulties requiring
surgical intervention; urinary retention/voiding
difficulties not requiring catheterisation or surgery
 Bowel obstruction
 Constipation
 Thrombosis/deep vein thrombosis (DVT)/
pulmonary embolism
 Urinary tract infection
 Wound infection
 Wound breakdown
 Other infection (sepsis, septicaemia, abscess)
 New, bothersome urinary tract symptoms
 Division of male sling
 Device exposure/extrusion which requires no
treatment or conservative treatment
 Device exposure/extrusion requiring hospitalisation
for surgical removal of the device
 Abnormal pain (acute or chronic, e.g. buttock or
groin pain/sciatica)
 New, bothersome sexual problems
 Death
Recording and reporting of SAEs in MASTER
Recording Non-serious events will be recorded in the
CRFs and participant questionnaires and collated for the
sponsor, but these will not be followed up further.
Planned primary care or hospital visits for conditions
other than those associated with UI or consequence of
surgery will not be collected or reported. Additional hos-
pital admissions (planned or unplanned) associated with
further UI treatment (e.g. further surgery) will be re-
corded as an outcome measure, but will not be reported
as serious adverse events. Relevant data will be collected
on the additional hospital admissions CRF.
Any SAEs related to the participants’ UI surgery that
are not further interventions (e.g. if a participant is ad-
mitted to hospital for treatment of infection) will be re-
corded on the serious adverse event form. In addition,
all deaths for any cause (related or otherwise) and related
life-threatening events will be recorded on the serious
adverse event form.
Reporting responsibilities of the CI When the SAE
form is uploaded onto the trial website, the CI or trial
manager will be automatically notified. If, in the opinion
of the local principal investigator (PI) and the CI, the
event is confirmed as being serious and related and
unexpected, the CI or trial manager will notify the sponsor
within 24 h of receiving the SAE notification. The CI or
trial manager will notify the sponsor of expected SAEs in
a timely fashion. The sponsor will provide an assessment
of the SAE. The CI (or trial manager) will report any
related and unexpected SAEs to the main Research Ethics
Committee (REC) and the DMC within 15 days of the CI
becoming aware of it. All related SAEs will be summarised
and reported to the Ethics Committee, the Funder and
the Trial Steering Committee in their regular progress
reports.
Discussion
The MASTER trial is the largest RCT evaluating the
effectiveness of AUS and the male sling for men who
have SUI after prostate surgery (for cancer or benign
disease). The results of MASTER will be used to determine
optimal treatment decisions for these men.
Trial status
The first participant was randomised into the trial on 29
January 2014, and the trial is currently open to recruitment
in 28 UK centres, with the last participant follow-up
expected in 31 December 2019.
MASTER protocol Version 4: 15 June 2017.
Endnotes
1Appropriate criteria for proof beyond reasonable
doubt cannot be specified precisely. A difference of at
least three standard deviation in the interim analysis of a
major endpoint may be needed to justify halting, or
modifying, such a study prematurely [17].
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Additional file 2: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents. (PDF 57 kb)
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Trial Steering Committee (TSC) Members
This committee comprises four independent members along with the CI (PA).
The other MASTER grant holders and key members of the central office (e.g.
the trial manager) may attend TSC meetings. The four independent members
are Howard Kynaston (Chair), Tom McNicholas (urologist), Suzanne Hagen
(statistician/methodologist), Neville Goodman (consumer representative).
Data Monitoring Committee (DMC) Members
This committee is comprised of three independent members (including an
independent statistician) and the CHaRT statistician. The CI or another trial
member can contribute to the open session as appropriate. The
independent members are Jonathan Cook (Chair/statistician), Mark
Speakman (urologist), John Parry (urologist).
Authorship and publication
The success of the study depends entirely on the wholehearted
collaboration of a large number of people undergoing incontinence surgery,
as well as their nurses and physicians. For this reason, chief credit for the
study will be given, not to the committees or central organisers, but to all
those who have collaborated in the study. The results of the study will be
reported first to study collaborators. The main report will be drafted by the
Project Management Group and circulated to all clinical collaborators for
comment. The final version will be agreed by the Trial Steering Committee
before submission for publication, on behalf of all the MASTER collaborators.
To safeguard the integrity of the main trial, reports of explanatory or satellite
studies will not be submitted for publication without prior agreement from
the Project Management Group.
We intend to maintain interest in the study by publication of MASTER
newsletters at intervals for participants, staff and collaborators. Once the
main report has been published, a lay summary of the findings will be sent
in a final MASTER newsletter to all involved in the trial.
Risks and benefits
The benefit to the men participating in the trial is the chance of receiving
the optimum treatment for that condition, although we do not know what
that treatment is. The risks are that they may have a sub-optimal operation
but any operation carries a risk, and it is not known which is optimal or more
risky. The benefit to participants, the NHS and society is that at the end of
the trial, it should be known whether one operation is more effective and
cost-effective than the other.
Information about risks and benefits and informed consent
Men will be informed of possible benefits and known risks of participation in
the trial by means of a PIL, discussion with the local research nurses and
their own consultant urologist. Patients will be having incontinence surgery
anyway, and we do not know that they will run additional risks by
participating in the trial. They will sign a consent form approved by the
Ethics Committee. They will be consented to participating in the study with
follow-up, being randomised, being contacted in the future about this and
other research including electronic tracing using NHS data, and data linkage
with computerised NHS data sources. Men who are not able or not willing to
be randomised will not be recruited but will be asked to consent to long-term
follow-up, including those who agreed to enter the non-randomised cohort
while that part of MASTER was open (up to and including 27 October 2015).
A standardised Surgical Information Sheet (SIS) will be used to provide
specific clinical information for men about the two surgical options,
including known complications.
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